ache in 3

AChE-IN-3 had inhibitory effect on AChE and stronger inhibitory effect on NO, with EC50 of 0.57 μM.

sEH/AChE-IN-3 (15) serves as a dual inhibitor targeting both soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), demonstrating potent activity and the ability to cross the blood-brain barrier (BBB). It exhibits IC50 values of 0.4 nM for human sEH (hsEH), 1.94 nM for human AChE (hAChE), 615 nM for human butyrylcholinesterase (hBChE), 4.3 nM for mouse sEH (msEH), and 2.61 nM for mouse AChE (mAChE), indicating its efficacy across these enzymes.

AChE/Aβ-IN-3 (Compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation, with IC₅₀ values of 1.29 and 4.93 μM, respectively. This compound exhibits antioxidant properties, reducing ROS and normalizing their levels. It is applicable in the study of neurological disorders such as Alzheimer's disease.

AChE/BChE-IN-3 (BMC-1) is a dual inhibitor of AChE and BChE, with IC50 values of 6.08 μM for electric eel AChE (elAChE) and 0.383 μM for equine serum BChE (eqBChE), respectively [1].

AChE/BChE-IN-3 (BMC-1) hydrochloride is a dual inhibitor of AChE and BChE, with IC50 values of 0.383 μM against equine serum BChE (eqBChE) and 6.08 μM against electric eel AChE (elAChE) [1].

AChE/BuChE-IN-3 is a potent inhibitor of AChE (IC50: 0.65 μM) and BuChE (IC50: 5.77 μM) that crosses the blood-brain barrier and inhibits the aggregation of Aβ1-42, suitable for Alzheimer's disease research.

AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, is a potent inhibitor of human monoamine oxidase B (MAO-B) with an IC50 of 0.0359 μM and also demonstrates significant inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.0473 μM and 0.0782 μM, respectively. Exhibiting notable antioxidant activity, AChE/BChE/MAO-B-IN-3 holds considerable promise for Alzheimer's disease (AD) research.

AChE/MAO-B-IN-3 is a dual inhibitor targeting both acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting inhibitory concentrations (IC50s) of 0.0257 μM and 0.0456 μM against human AChE and MAO-B, respectively. This compound holds potential for Alzheimer's disease research.

Dual AChE-MAO B-IN-3 (Compound C10) is a potent inhibitor of both AChE and MAO-B, with IC50 values of 0.58 μM and 0.41 μM, respectively. It targets the catalytic anionic site and peripheral anionic site of AChE, making it relevant for Alzheimer's disease (AD) research [1].

AChE/BACE1/GSK3β-IN-1 is an orally active, blood-brain barrier-permeable, moderately bioavailable triple inhibitor of AChE, BACE1, and GSK3β, utilized for Alzheimer's disease (AD) research.

AChE/GSK-3β-IN-1 is a potent dual AChE/GSK-3β inhibitor that crosses the blood-brain barrier and acts on hAChE (IC50: 1.2 nM), hBChE (IC50: 149.8 nM) and hGSK-3β (IC50: 22.4 nM). AChE/GSK-3β-IN-1 is able to occupy the ATP binding site of DYRK1A. aChE/GSK-3β-IN-1 exhibits high kinase selectivity for the CMGC kinase family. aChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. aChE/GSK-3β-IN-1 can be used to study Alzheimer's disease.

ACHE-IN-38 is a potent Acetylcholinesterase inhibitor that can be used for the synthesis of compounds with anti-inflammatory, anti-tumor, and antibacterial activities.

hAChE-IN-3 (compound 5c) serves as a potent inhibitor for AChE, BuChE, MAO-B, and BACE-1, with respective IC50 values of 0.44, 0.08, 5.15, and 0.38 μM, demonstrating its ability to cross the blood-brain barrier. This compound also exhibits antioxidant properties and metal chelation capabilities. Additionally, it targets peripheral anion sites, potentially modulating β-amyloid and ameliorating neurodegeneration linked to Alzheimer's disease, highlighting its research potential for this condition [1].

eeAChE-IN-3 (compound YS3g) is an orally bioavailable and potent inhibitor of EeAChE and IL-6, with IC50 values of 0.54 μM for EeAChE, 0.49 μM for RatAChE, 8.54 μM for RatBuChE, and 0.57 μM for IL-6. It can enhance learning and memory deficits in mice induced by STZ (streptozotocin) and shows potential for Alzheimer's disease (AD) research.

AChE-IN-39 (Compound 7c), with an IC50 value of 0.058 μM, is an acetylcholinesterase (AChE) inhibitor known for its DPPH scavenging activity and potential to ameliorate cognitive impairments in an aluminum chloride (AlCl3)-induced amnesia animal model, suggesting its usefulness in Alzheimer's disease research [1].

AChE-IN-31 (compound 1), a non-competitive acetylcholinesterase (AChE) inhibitor, exhibits potential for Alzheimer's disease research [1].

AChE-IN-30 is an acetylcholinesterase (AChE) inhibitor exhibiting neuroprotective effects with an inhibitory concentration (IC 50) of 4.4 μM. It prevents hydrogen peroxide (H 2 O 2)-induced apoptosis by inhibiting the accumulation of reactive oxygen species (ROS) within cells and is utilized in Alzheimer's disease research [1].

AChE-IN-34 (compound 5l) is a potent and selective AChE inhibitor with an IC50 of 3.98 µM, exhibiting negligible BChE inhibition. It demonstrates mixed-mode inhibition of AChE with a Ki of 0.044 µM using acetylthiocholine substrate concentrations ranging from 0.1-1 mM [1].

AChE-IN-35 (compound 5g) is an acetylcholinesterase inhibitor with an IC50 value of 5.88 μM [1].

AChE-IN-36 (compound A4) is an acetylcholinesterase inhibitor with an IC50 of 0.04 μM, affecting ROS levels and modulating NRF2 gene expression [1].

AChE-IN-37 (compound A2) is an acetylcholinesterase inhibitor with an IC50 of 0.23 µM, altering reactive oxygen species (ROS) levels and modulating the expression of nuclear factor erythroid 2-related factor 2 (NRF2) [1].

hBChE-IN-3 (compound 30) serves as both an activator of carbonic anhydrase (CA) and an inhibitor of cholinesterase (ChE), exhibiting IC50 values of 7.4 nM for AchE and 1.9 nM for BchE. This compound is utilized in the research of neurodegenerative and psychiatric disorders.

AChE-IN-92 (Compound L4R1-3) is a highly selective acetylcholinesterase (AChE) inhibitor with an IC50 of 4.6 nM. It effectively prevents the hydrolysis of acetylcholine, thereby increasing its levels in the synaptic cleft. AChE-IN-92 holds potential for research in Alzheimer's disease (AD).

Acotiamide is an orally active, selective, and reversible acetylcholinesterase (AChE) inhibitor with an IC50 of 1.79 μM. It is a gastroprokinetic agent that enhances gastric contractility and accelerates delayed gastric emptying, with potential for research in functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory [1] [2] [3].